default author photo

Mohammad Bohlooly-Y

AstraZeneca Pharmaceuticals - IMED Biotech Unit

Mölndal

Sweden

SCHOLARLY PAPERS

3

DOWNLOADS

159

TOTAL CITATIONS

1

Scholarly Papers (3)

1.

PCSK9 rs11591147 R46L Loss-of-Function Variant Protects Against Liver Damage in Individuals with NAFLD

Number of pages: 34 Posted: 19 May 2020
- Section of Gastroenterology and Hepatology, AstraZeneca Pharmaceuticals - Bioscience Metabolism, Research and Early Development Cardiovascular, Renal and Metabolism (CVRM), Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Parma - Dipartimento di Economia, University of Gothenburg - Department of Molecular and Clinical Medicine, University of Eastern Finland - Department of Clinical Nutrition, AstraZeneca Pharmaceuticals - Bioscience Metabolism, Research and Early Development Cardiovascular, Renal and Metabolism (CVRM), AstraZeneca Pharmaceuticals - Bioscience Cardiovascular, Research and Early Development Cardiovascular, Renal and Metabolism, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico - General Medicine and Metabolic Diseases, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Florence - Department of Experimental and Clinical Medicine, University of Eastern Finland - Department of Medicine, affiliation not provided to SSRN, AstraZeneca Pharmaceuticals - IMED Biotech Unit, - Section of Gastroenterology and Hepatology, - Biomedical Department of Internal and Specialized Medicine (DI.BI.M.I.S.), Magna Graecia University of Catanzaro - Department of Experimental and Clinical Medicine, - Section of Gastroenterology and Hepatology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico - General Medicine and Metabolic Diseases, University of Milan - Department of Pathophysiology and Transplantation, University of Gothenburg - Department of Molecular and Clinical Medicine and - Section of Gastroenterology and Hepatology
Downloads 83 (783,685)

Abstract:

Loading...

NASH, NAFLD, FIBROSIS, PCSK9

2.

Network Analyses Links Epicardial Fat Metabolism to Human Coronary Heart Disease

Number of pages: 37 Posted: 16 Apr 2021
King’s College London - Centre for Host-Microbiome Interactions, Royal Institute of Technology (KTH) - Science for Life Laboratory (SciLife Lab), AstraZeneca Pharmaceuticals - IMED Biotech Unit, AstraZeneca Pharmaceuticals - Bioscience Metabolism, Research and Early Development Cardiovascular, Renal and Metabolism (CVRM), AstraZeneca Pharmaceuticals - IMED Biotech Unit, University of Gothenburg - Department of Molecular and Clinical Medicine, University of Gothenburg - Department of Molecular and Clinical Medicine, Royal Institute of Technology (KTH) - Science for Life Laboratory (SciLife Lab) and University of Gothenburg - Department of Molecular and Clinical Medicine
Downloads 52 (1,041,696)

Abstract:

Loading...

3.

Therapeutic Genome Editing With CRISPR/Cas9 in a Humanized Mouse Model Ameliorates A1-Antitrypsin Deficiency Phenotype

Number of pages: 32 Posted: 08 Apr 2018
AstraZeneca Pharmaceuticals - IMED Biotech Unit, AstraZeneca Pharmaceuticals - IMED Biotech Unit, AstraZeneca Pharmaceuticals - IMED Biotech Unit, AstraZeneca Pharmaceuticals - IMED Biotech Unit, AstraZeneca Pharmaceuticals - IMED Biotech Unit, AstraZeneca Pharmaceuticals - IMED Biotech Unit, AstraZeneca Pharmaceuticals - IMED Biotech Unit, AstraZeneca Pharmaceuticals - IMED Biotech Unit, AstraZeneca Pharmaceuticals - IMED Biotech Unit, AstraZeneca Pharmaceuticals - IMED Biotech Unit, AstraZeneca Pharmaceuticals - IMED Biotech Unit, AstraZeneca Pharmaceuticals - IMED Biotech Unit, AstraZeneca Pharmaceuticals - IMED Biotech Unit and AstraZeneca Pharmaceuticals - IMED Biotech Unit
Downloads 24 (1,399,036)
Citation 1

Abstract:

Loading...